Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Although elevated activity of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) has been proposed to mediate comorbid depression in inflammatory disorders, its causative role has never been tested. We report that peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests. Blockade of IDO activation either indirectly with the anti-inflammatory tetracycline derivative minocycline, that attenuates LPS-induced expression of proinflammatory cytokines, or directly with the IDO antagonist 1-methyltryptophan (1-MT), prevents development of depressive-like behavior. Both minocycline and 1-MT normalize the kynurenine/tryptophan ratio in the plasma and brain of LPS-treated mice without changing the LPS-induced increase in turnover of brain serotonin. Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose dependently induces depressive-like behavior. These results implicate IDO as a critical molecular mediator of inflammation-induced depressive-like behavior, probably through the catabolism of tryptophan along the kynurenine pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“depressive-like behaviors in rodents are mediated by an enzyme that degrades tryptophan, called indoleamine 2,3dioxygenase (IDO; O'Connor et al., 2009; see also Maes et al., 2011)”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as O'Connor et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal studies have shown that inflammation promotes a pattern of behavior known as sickness behavior that includes symptoms of depression, such as fatigue, anhedonia, and social withdrawal.[10,11]”
From SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: Research Article: Suicidal Ideation and Inflammation (2013) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, blocking glutamate receptors with ketamine or inhibiting IDO activity protects mice from LPS- or stress-induced depressive-like behaviour but leaves the inflammatory response intact85,86.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [86]
Experimental — accuracy not yet measuredIn the citing paper
“In preclinical models, LPS-induced depressive behavior is mediated by IDO activation (O’Connor et al., 2009).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as O’Connor et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Self-citationPrevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Mood disorders in the medically ill: scientific review and recommendations
Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R. R., Nemeroff, C. B., Bremner, J. D., Carney, R. M., Coyne, J. C., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.001 · Cited by 1,071
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Cytokine-induced sickness behaviour: mechanisms and implications
Konsman, J. P., Parnet, P., & Dantzer, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02088-9 · Cited by 999
Self-citation
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
“For example, administration of KYN alone has been shown to induce depressive-like behavior in mice (28).”
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
“…for this tryptophan depletion hypothesis of depression is provided by animal model studies, which have shown that depressive-like behaviors in rodents are mediated by an enzyme that degrades tryptophan, called indoleamine 2,3-dioxygenase (IDO; O’Connor et al., 2009; see also Maes et al., 2011).”
BackgroundThe Bidirectional Relationship of Depression and Inflammation: Double Trouble
Beurel, E., Toups, M., & Nemeroff, C. B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.002 · Cited by 2,136
“Consistent with this, in rodents, administration of L-kynurenine induced depressivelike behaviors, whereas LPS-induced depressive-like behaviors are blocked by an IDO competitive inhibitor (O’Connor et al., 2009a, 2009b).”
BackgroundSerotonin, tryptophan metabolism and the brain-gut-microbiome axis
O’Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.027 · Cited by 2,012
Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott, K., Moloney, G., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.019 · Cited by 1,683
“…3-dioxygenase (IDO), an enzyme induced by cytokines, and tryptophan-2,3-dioxygenase (TDO), the expression of which can be induced by circulating glucocorticoids (O'Connor et al., 2009) and has been reported to be regulated by the gut microbiota during colonization (El Aidy et al., 2014).”
BackgroundImmune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
“Abbreviations ACC Anterior Cingulate Cortex ACTH Adrenocorticotropic Hormone BCG Bacille Calmette-Guerin BDNF Brain Derived Neurotrophic Factor BH4 Tetrahydrobiopterin BMI Body Mass Index CNS Central Nervous System COX Cyclooxygenase CRH Corticotropin-Releasing Hormone Pharmacol Ther.”
BackgroundMethodInfluentialInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
“…5HIAA/5-HT ratios, in brain regions such as the cortex and nucleus accumbens (Song et al., 1999, De La Garza and Asnis, 2003), and these changes in 5-HT turnover occur in concert with the appearance of later, more persistent depressive-like behaviors (Frenois et al., 2007, O'Connor et al., 2009b).”
BackgroundInfluentialNeuroimmune Interactions: From the Brain to the Immune System and Vice Versa
Dantzer, R. (2018) · Physiological Reviews · doi:10.1152/physrev.00039.2016 · Cited by 1,073
Self-citationBercik, P., Park, A. J., Sinclair, D., Khoshdel, A., Lu, J., Huang, X., Deng, Y., Blennerhassett, P. A., Fahnestock, M., Moine, D., et al. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01796.x · Cited by 1,018
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415174111 · Cited by 972
Depression as a Microglial Disease
Yirmiya, R., Rimmerman, N., & Reshef, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.001 · Cited by 944
“However, another study found no antidepressant-like effects of minocycline (albeit at somewhat lower doses) in the forced swim test [87]; (ii) in the LPS model of depression in rats, administration of minocycline completely prevented the development of depression-like symptoms, as well as the LPS-induced increase in 5…”
BackgroundResultMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
“In that report, minocycline’s ability to block IDO induction prevented depressive-like immobility (O’Connor et al., 2009).”
BackgroundThe vascular depression hypothesis: mechanisms linking vascular disease with depression
Taylor, W. D., Aizenstein, H. J., & Alexopoulos, G. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.20 · Cited by 923
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
“(O”Connor et al. 2008).”
Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013) · Depression and Anxiety · doi:10.1002/da.22084 · Cited by 892
“of both the administration of endotoxin and infection with the mycobacterium, Bacille Calmette-Guerin (BCG).[56,57] Indeed, inhibition of IDO using 1 methyl-tryptophan (1-MT) or the use of IDO deficient mice has been shown to reverse the depressogenic effects of endotoxin and BCG in mice.”
MethodLeonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Review: microglia of the aged brain: primed to be activated and resistant to regulation
Norden, D. M., & Godbout, J. P. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01306.x · Cited by 792
Cytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789
Self-citationInflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
Self-citationMaes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Henry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., Sheridan, J. F., & Godbout, J. P. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-15 · Cited by 678
Bercik, P., Verdu, E. F., Foster, J. A., Macri, J., Potter, M., Huang, X., Malinowski, P., Jackson, W., Blennerhassett, P., Neufeld, K. A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.063 · Cited by 674
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Self-citationKim, Y.-K., Na, K.-S., Myint, A.-M., & Leonard, B. E. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.008 · Cited by 620
Brites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599
“peripheral administration of LPS in mice caused sickness, increased immobility in the tail suspension test and depressivelike behavior in the forced swim test, together with a delayed cellular activity (Frenois et al., 2007; O’Connor et al., 2009).”
BackgroundThe role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
“Furthermore, injecting the bacterial endotoxin lipopolysaccharide (LPS) was shown to induce inflammation and to cause subsequent depressive-like behavior in rodents (O’Connor et al., 2009; Ohgi et al., 2013).”
Henry, C. J., Huang, Y., Wynne, A. M., & Godbout, J. P. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.09.002 · Cited by 565
“IDO activation is relevant because IDO-dependent tryptophan metabolism is associated with inflammatory-mediated depressive-like behavior (Dantzer et al. 2008; Godbout et al. 2007; O’Connor et al. 2008).”
BackgroundGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
“Moreover, administration of KYN to naive mice dose dependently induces depressive-like behaviour (O'Connor et al., 2009).”
BackgroundMaes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.014 · Cited by 544
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
Animal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
“A key priority in this field will be to progress from focusing on the sickness behavior induced by strong immune stimuli such as LPS (lipopolysaccharide) (O’Connor et al. 2009) to the behavioral consequences of more elegant manipulations of specific cytokine signaling axes, as well as defining the therapeutic relevanc…”
BackgroundO'Connor, J. C., André, C., Wang, Y., Lawson, M. A., Szegedi, S. S., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5032-08.2009 · Cited by 502
Self-citationMacrophage de novo NAD+ synthesis specifies immune function in aging and inflammation
Minhas, P. S., Liu, L., Moon, P. K., Joshi, A. U., Dove, C., Mhatre, S., Contrepois, K., Wang, Q., Lee, B. A., Coronado, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0255-3 · Cited by 501
Inflammation in psychiatric disorders: what comes first?
Bauer, M. E., & Teixeira, A. L. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13712 · Cited by 500
Animal models of major depression: drawbacks and challenges
Planchez, B., Surget, A., & Belzung, C. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02084-y · Cited by 480
Oxidative stress, inflammation and treatment response in major depression
Lindqvist, D., Dhabhar, F. S., James, S. J., Hough, C. M., Jain, F. A., Bersani, F. S., Reus, V. I., Verhoeven, J. E., Epel, E. S., Mahan, L., et al. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.031 · Cited by 473
“…the so called “evil twins of aging” Joseph et al., 2005), may also be involved in the pathophysiolgy of MDD and may be related to treatment response (Berk et al., 011; Dantzer et al., 2008; Maes, 2011; Miller, 2010; Ng et al., 2008; aison et al., 2006; Schiepers et al., 2005; Uher et al., 2014).”
BackgroundInflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
The role of inflammation and the gut microbiome in depression and anxiety
Peirce, J. M., & Alviña, K. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24476 · Cited by 466
“…depressive‐like behavior in murines suggest that IDO activation plays a causal role in neuroinflammatory mood disorders by promoting the release of these neurotoxins (Dobos et al., 2012; O'Connor et al., 2009; Parrott et al., 2016; Smith et al., 2013; Walker et al., 2013; Wichers et al., 2005).”
BackgroundNeuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460
“Finally, it is unlikely that these effects are a result of reduced tryptophan and thus lower serotonin turnover, as these mice display increased central kynurenine levels without central loss of tryptophan, and serotonin turnover actually increases (O’Connor et al., 2009c; Walker et al., 2013).”
BackgroundResultInfluentialSelf-citationIzquierdo, I., Furini, C. R. G., & Myskiw, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00018.2015 · Cited by 453
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Walker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432
Self-citationImmune–neural connections: how the immune system’s response to infectious agents influences behavior
McCusker, R. H., & Kelley, K. W. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.073411 · Cited by 429
Self-citationFelger, J. C., & Miller, A. H. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.09.003 · Cited by 391
“Although early hypotheses regarding IDO and depression were focused on the consequence of tryptophan depletion on serotonin synthesis, more recent data indicate that kynurenine administration alone is sufficient to induce depressive-like behavior in laboratory animals [151].”
BackgroundGuo, L.-T., Wang, S.-Q., Su, J., Xu, L.-X., Ji, Z.-Y., Zhang, R.-Y., Zhao, Q.-W., Ma, Z.-Q., Deng, X.-Y., & Ma, S.-P. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1474-8 · Cited by 401
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Systemic Immune Activation Leads to Neuroinflammation and Sickness Behavior in Mice
Biesmans, S., Meert, T. F., Bouwknecht, J. A., Acton, P. D., Davoodi, N., De Haes, P., Kuijlaars, J., Langlois, X., Matthews, L. J. R., Ver Donck, L., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/271359 · Cited by 382
“Some groups showed that LPS-treated mice display increased immobility in the tail suspension and forced swim test at 24 h, a time point at which motor activity in the open field test had returned to baseline [23, 24].”
BackgroundInterleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
“For example, administration of LPS in rodents activates IDO and induces depressive-like symptoms, which in turn can be prevented by an IDO antagonist (O’Connor et al, 2009).”
Correia, A. S., & Vale, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158493 · Cited by 350
“Indeed, LPS exposure increased brains’ IDO mRNA expression in rodents, resulting in overactivation of the Kyn pathway [79].”
BackgroundEmerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Bower, J. E., & Lamkin, D. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.011 · Cited by 372
Gut microbial molecules in behavioural and neurodegenerative conditions
Needham, B. D., Kaddurah-Daouk, R., & Mazmanian, S. K. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-00381-0 · Cited by 379
Immune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348
Cao, P., Chen, C., Liu, A., Shan, Q., Zhu, X., Jia, C., Peng, X., Zhang, M., Farzinpour, Z., Zhou, W., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.012 · Cited by 344
Beumer, W., Gibney, S. M., Drexhage, R. C., Pont-Lezica, L., Doorduin, J., Klein, H. C., Steiner, J., Connor, T. J., Harkin, A., Versnel, M. A., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212100 · Cited by 347
The neuroimmune basis of fatigue
Dantzer, R., Heijnen, C. J., Kavelaars, A., Laye, S., & Capuron, L. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.10.003 · Cited by 346
Self-citationIrritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 331
Depression and immunity: A role for T cells?
Miller, A. H. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.09.009 · Cited by 337
“IDO activation and kynurenine administration have been associated with depressive-like behavior in rodents (O’Connor et al., 2009a, 2009b).”
BackgroundCytokines and Glucocorticoid Receptor Signaling
Pace, T. W. W., & Miller, A. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04984.x · Cited by 339
Immune suppression and immune activation in depression
Blume, J., Douglas, S. D., & Evans, D. L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.008 · Cited by 338
Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression
Kim, H., Chen, L., Lim, G., Sung, B., Wang, S., McCabe, M. F., Rusanescu, G., Yang, L., Tian, Y., & Mao, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61884 · Cited by 324
Zunszain, P. A., Hepgul, N., & Pariante, C. M. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_211 · Cited by 303
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
The role of neuroimmune signaling in alcoholism
Crews, F. T., Lawrimore, C. J., Walter, T. J., & Coleman, L. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.031 · Cited by 321
“IDO generates the compound kynurenine, which has been shown to induce depression-like behavior (O'Connor et al., 2009).”
Zheng, Z.-H., Tu, J.-L., Li, X.-H., Hua, Q., Liu, W.-Z., Liu, Y., Pan, B.-X., Hu, P., & Zhang, W.-H. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.007 · Cited by 304
Zhu, C.-B., Lindler, K. M., Owens, A. W., Daws, L. C., Blakely, R. D., & Hewlett, W. A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.116 · Cited by 317
O'Connor, J. C., Lawson, M. A., André, C., Briley, E. M., Szegedi, S. S., Lestage, J., Castanon, N., Herkenham, M., Dantzer, R., & Kelley, K. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802722 · Cited by 295
Self-citationWon, E., & Kim, Y.-K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113006 · Cited by 300
“The authors confirm that this article content has no conflict of interest.”
BackgroundGodbout, J. P., Moreau, M., Lestage, J., Chen, J., Sparkman, N. L., Connor, J. O., Castanon, N., Kelley, K. W., Dantzer, R., & Johnson, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301649 · Cited by 299
Self-citationZhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289
Skelly, D. T., Hennessy, E., Dansereau, M.-A., & Cunningham, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069123 · Cited by 274
Microglia in depression: current perspectives
Jia, X., Gao, Z., & Hu, H. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1815-6 · Cited by 282
Wagner, K. M., McReynolds, C. B., Schmidt, W. K., & Hammock, B. D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.006 · Cited by 270
“The rate limiting enzyme indoleamine 2,3-dioxygenase (IDO) that metabolizes tryptophan and thereby limits serotonin production is under regulation of inflammatory cytokines (O'Connor et al., 2009; Oxenkrug, 2010).”
BackgroundZhao, X., Cao, F., Liu, Q., Li, X., Xu, G., Liu, G., Zhang, Y., Yang, X., Yi, S., Xu, F., et al. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.05.064 · Cited by 280
The role of the innate immune system in psychiatric disorders
Jones, K. A., & Thomsen, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.10.002 · Cited by 274
“…a study of serotonin turnover in the brains of LPS-treated rats revealed no reduction of tryptophan or serotonin levels in brain even though tryptophan in the periphery was substantially reduced (O'Connor et al., 2009b), suggesting that L-tryptophan metabolism occurs in a separate pool in the CNS.”
InfluentialSavitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272
Self-citationCross talk: the microbiota and neurodevelopmental disorders
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271
Salazar, A., Gonzalez-Rivera, B. L., Redus, L., Parrott, J. M., & O'Connor, J. C. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.03.010 · Cited by 263
Self-citationBrain microglia in psychiatric disorders
Mondelli, V., Vernon, A. C., Turkheimer, F., Dazzan, P., & Pariante, C. M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30101-3 · Cited by 265
Oxenkrug, G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8497-4 · Cited by 254
“There are two indirect (via downregulation of IFNG formation) IDO inhibitors available for human use: minocycline, an antibiotic with anti-inflammatory action [101, 102], and Wellbutrin, an antidepressant [103].”
Shelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 261
Effects of obesity on depression: A role for inflammation and the gut microbiota
Schachter, J., Martel, J., Lin, C.-S., Chang, C.-J., Wu, T.-R., Lu, C.-C., Ko, Y.-F., Lai, H.-C., Ojcius, D. M., & Young, J. D. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.08.026 · Cited by 253
“Accordingly, IDO activation has been observed in mice treated intraperitoneally with LPS, which increases IFN-c and TNF-a levels and induces depression symptoms (O’Connor et al., 2009).”
MethodMiller, A. H. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.08.006 · Cited by 261
“For example, inhibition of IDO activity by the IDO antagonist, 1-methyltryptophan, has been shown to block the development of depressive-like symptoms in mice following administration of lipopolysaccharide (LPS) (O’Connor et al., 2008).”
InfluentialRole of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder
Needham, B. D., Adame, M. D., Serena, G., Rose, D. R., Preston, G. M., Conrad, M. C., Campbell, A. S., Donabedian, D. H., Fasano, A., Ashwood, P., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.09.025 · Cited by 247
Liu, R. T., Rowan-Nash, A. D., Sheehan, A. E., Walsh, R. F. L., Sanzari, C. M., Korry, B. J., & Belenky, P. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.03.026 · Cited by 242
Blednov, Y. A., Benavidez, J. M., Geil, C., Perra, S., Morikawa, H., & Harris, R. A. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.01.008 · Cited by 239
“LPS doses in the range of 0.8–5 mg/kg are commonly used to produce longer-lasting effects of LPS such as depressive-like behavior and neurodegeneration (O’Connor et al., 2009; Qin et al., 2008).”
MethodInfluentialRole of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches
Dantzer, R. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_6 · Cited by 248
“On the basis of these results, we were able to move to the next step in this research and demonstrate that IDO activation is crucial for the transition from sickness behavior to depression-like behavior in both LPS-treated and BCG-treated mice [12–14].”
BackgroundResultSelf-citationNajjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-142 · Cited by 248
Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders
Gibney, S. M., & Drexhage, H. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9462-8 · Cited by 234
André, C., Dinel, A.-L., Ferreira, G., Layé, S., & Castanon, N. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.03.012 · Cited by 241
Self-citationLi, M., Li, C., Yu, H., Cai, X., Shen, X., Sun, X., Wang, J., Zhang, Y., & Wang, C. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0964-9 · Cited by 239
“The mechanisms of central or peripheral treatment with LPS on behavioral dysfunctions in rodents trigger an increase in the expression of pro-inflammatory cytokines [7, 34, 35].”
BackgroundBehl, T., Rana, T., Alotaibi, G. H., Shamsuzzaman, M., Naqvi, M., Sehgal, A., Singh, S., Sharma, N., Almoshari, Y., Abdellatif, A. A. H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112545 · Cited by 221
Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Kynurenines: from the perspective of major psychiatric disorders
Myint, A. M. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08551.x · Cited by 229
The role of the gut microbiota in dietary interventions for depression and anxiety
Bear, T. L. K., Dalziel, J. E., Coad, J., Roy, N. C., Butts, C. A., & Gopal, P. K. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa016 · Cited by 229
“Other mechanisms found to be linked to depression include a dysfunctional hypothalamic– pituitary–adrenal (HPA) axis (38); immune-inflammatory, oxidative, and nitrosative pathways (39–42, 30, 43–48); neuroinflammation (including activated microglial cells) (43); altered vagus nerve tone (49); neurotrophic changes, inc…”
BackgroundGibney, S. M., McGuinness, B., Prendergast, C., Harkin, A., & Connor, T. J. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.010 · Cited by 221
Metadata
- Authors
- O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R.
- Affiliations
- University of Illinois Urbana-Champaign (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Dantzer, R
- Venue
- Molecular Psychiatry
- Published
- 2008-01-15
- Volume
- 14
- Issue
- 5
- Pages
- 511-522
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC2683474
- OpenAlex
- W2050508296
- Cited by
- 1,278
- References
- 56
- Citations by year
- 2026: 45 · 2025: 68 · 2024: 82 · 2023: 86 · 2022: 94 · 2021: 106 · 2020: 88 · 2019: 86 · 2018: 95 · 2017: 87 · 2016: 88 · 2015: 76 · 2014: 61 · 2013: 71 · 2012: 38
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R01AG029573)
- National Institute of Mental Health (R01MH079829, R01MH071349, R01 MH-71349)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK059802, T32 DK59802-01)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- indoleamine 2,3-dioxygenase, lipopolysaccharide, depression-like behavior, kynurenine pathway, tryptophan catabolism, minocycline, 1-methyltryptophan, L-kynurenine, kynurenine/tryptophan ratio, serotonin turnover, inflammatory cytokines, comorbid depression
- MeSH terms
- Animals, Behavior, Animal, Chromatography, High Pressure Liquid, Cytokinins, Depression, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme Activation, Enzyme Inhibitors, Gene Expression Regulation, Kynurenine, Lipopolysaccharides, Male, Mice, Inbred ICR, Minocycline, Motor Activity, Swimming, Time Factors, Tryptophan, Hindlimb Suspension, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.